Rapid Acting Antidepressants

The Advances in Pharmacology series presents a variety of chapters from the best authors in the field.

Includes the authority and expertise of leading contributors in pharmacology Presents the latest release in the Advances in Pharmacology series

Part I – Neurobiology of ketamine effects

1. Effects of ketamine and other rapidly acting antidepressants on hippocampal excitatory and inhibitory transmission

Allie J. Widman and Lori L. McMahon

2. Antidepressant mechanisms of ketamine: Focus on GABAergic inhibition

Bernhard Luscher, Mengyang Feng and Sarah J. Jefferson

3. The role of eEF2 kinase in the rapid antidepressant actions of ketamine

Kanzo Suzuki and Lisa M. Monteggia

Part II – The rapid therapeutic effects of ketamine

4. Clinical overview of NMDA-R antagonists and clinical practice

Pasha A. Davoudian and Samuel T. Wilkinson

5. Ketamine for depression clinical issues

Syed Z. Iqbal and Sanjay J. Mathew

6. Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence

Lynnette A. Averill, Samar Fouda, James W. Murrough and Chadi G. Abdallah

7. Neurobiological biomarkers of response to ketamine

Bashkim Kadriu, Elizabeth D. Ballard, Ioline D. Henter, Stephen Murata, Nimesha Gerlus and Carlos A. Zarate Jr

8. Relapse prevention in treatment resistant major depressive disorder with rapid-acting antidepressants

Jaskaran B. Singh, Maggie Fedgchin, Ella J. Daly and Wayne C. Drevets

9. The emergence of ketamine as a novel treatment for posttraumatic stress disorder

Adriana Feder, Sarah B. Rutter, Daniela Schille and Dennis S. Charney

Part III – Novel rapid-acting antidepressant mechanisms related to ketamine

10. mGlu2/3 receptor as a novel target for rapid acting antidepressants

Shigeyuki Chaki

11. Involvement of muscarinic receptor mechanisms in antidepressant drug action

Jeffrey M. Witkin, Jodi L. Smith, Lalit K. Golani, Emily A. Brooks and Anna E. Martin

12. The antidepressant efficacy of the muscarinic antagonist scopolamine: Past findings and future directions